Can Fite Gross Profit vs. Current Valuation
| CANF Stock | USD 1.62 0.02 1.25% |
Gross Profit | First Reported 2010-09-30 | Previous Quarter 158 K | Current Value 158 K | Quarterly Volatility 438.4 K |
For Can Fite profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Can Fite to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Can Fite Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Can Fite's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Can Fite Biopharma over time as well as its relative position and ranking within its peers.
Can |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Can Fite Biopharma Current Valuation vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. Can Fite Biopharma is rated below average in gross profit category among its peers. It is rated below average in current valuation category among its peers reporting about 5.57 of Current Valuation per Gross Profit. At this time, Can Fite's Gross Profit is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Can Fite by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Can Current Valuation vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Can Fite |
| = | 810 K |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Can Fite |
| = | 4.51 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Can Current Valuation vs Competition
Can Fite Biopharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.61 Billion. Can Fite adds roughly 4.51 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Can Fite Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Can Fite, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Can Fite will eventually generate negative long term returns. The profitability progress is the general direction of Can Fite's change in net profit over the period of time. It can combine multiple indicators of Can Fite, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1 M | 963.6 K | |
| Operating Income | -8.2 M | -8.6 M | |
| Income Before Tax | -7.6 M | -8 M | |
| Total Other Income Expense Net | 561 K | 533 K | |
| Net Loss | -7.6 M | -8 M | |
| Income Tax Expense | 1.00 | 0.95 | |
| Net Loss | -9 M | -9.5 M | |
| Net Loss | -11.7 M | -12.3 M | |
| Interest Income | 506 K | 287.6 K | |
| Net Interest Income | 726 K | 762.3 K | |
| Change To Netincome | 695.8 K | 730.5 K | |
| Net Loss | (0.01) | (0.01) | |
| Income Quality | 1.11 | 0.80 | |
| Net Income Per E B T | 0.93 | 0.79 |
Can Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Can Fite. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Can Fite position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Can Fite's important profitability drivers and their relationship over time.
Use Can Fite in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Can Fite position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Can Fite will appreciate offsetting losses from the drop in the long position's value.Can Fite Pair Trading
Can Fite Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Can Fite could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Can Fite when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Can Fite - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Can Fite Biopharma to buy it.
The correlation of Can Fite is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Can Fite moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Can Fite Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Can Fite can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Can Fite position
In addition to having Can Fite in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Allocation ETFs Thematic Idea Now
Asset Allocation ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 145 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Can Fite's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Can Fite Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Can Fite's income statement, its balance sheet, and the statement of cash flows.